Immunomedics Inc. has filed for Canadian governmentapproval to market its ImmuRaid-CEA colorectal cancerimaging agent, the company said Thursday.
ImmuRaid, which the FDA is reviewing in the United States,consists of a monoclonal antibody fragment labeled withtechnetium-99.
Shares of the Warren, N.J., company (NASDAQ:IMMU) closed up13 cents at $12.13 on Friday.
(c) 1997 American Health Consultants. All rights reserved.